BridgeBio Reports Third Quarter 2026
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from operations was $11.6 million, driven by increased revenue and a one-time $75.0 million BEYONTTRA sales milestone from Bayer. Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026, fully funding all three launches and expansion indications
- Attruby growth was again led by the treatment-naïve segment, with both the number of newly diagnosed patients starting treatment and Attruby's share of those starts increasing
- Real-world evidence continues to differentiate acoramidis from tafamidis on outcomes that matter to patients, physicians, and payers: (i) an independent Epic COSMOS analysis of 2,684 patients found an 18% lower risk of death, hospitalization, new atrial fibrillation or diuretic escalation (p<0.01) with a 25% lower risk of hospitalization with acoramidis (p<0.001); (ii) the first peer-reviewed real-world comparison of TTR stabilizers found 34% less clinical worsening with acoramidis (p=0.046)
- Cardiac MRI from ATTRibute-CM and its extension showed evidence of potential reversal of structural damage and functional decline through 42 months for patients on acoramidis, with up to half of completers achieving clinically meaningful improvement in heart function. The first participant was dosed in ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with Attruby
- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review. Launch preparation is well advanced, with 70% of patients concentrated at MDA Care Centers, over 70% of which the field team has reached with a 90% target by PDUFA. Based on interactions with EU national health authorities, the Company intends to submit an MAA to the EMA in the first half of 2028
- Oral infigratinib for achondroplasia has a February 4, 2027 PDUFA date, with Priority Review. The MAA is now under EMA review with potential EU approval in the second half of 2027. Launch preparation is well advanced, with the U.S. field team fully staffed. In hypochondroplasia, the Phase 2/3 ACCEL study is expanding to higher doses to find the optimal dose, supported by safety data from PROPEL 3 and PROPEL OLE
- Encaleret for ADH1 has a May 8, 2027 PDUFA date, with Priority Review, and the MAA is under EMA review with potential EU approval in the second half of 2027. Launch preparation is well advanced, with >600 genetically confirmed patients identified, up from approximately 500 last quarter, and the U.S. field team is fully deployed
- The first participant was dosed in RECLAIM-HP, the Phase 3 study for encaleret in chronic hypoparathyroidism. Topline data are expected in early 2028, representing a potential second indication in an estimated population of 200,000 patients in the U.S. and EU
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today its financial results for the third quarter ended September 30, 2026, and provided an update on Attruby’s commercial progress. 1 Pipeline Overview:
Status Approved in U.S., EU, Japan, Switzerland, Brazil, U.K., and Australia PDUFA date set for Next expected milestone November 27, 2026, with New data to be shared Program Priority Review at AHA 2026 Acoramidis for ATTR-CM PDUFA date set for U.S. launch upon FDA BBP-418 for LGMD2I/R9 February 4, 2027, with approval Oral infigratinib for Priority Review; MAA U.S. launch upon FDA achondroplasia submitted to EMA approval ────────────────────────────────────────────────────────────────────────────── PDUFA date set for May Encaleret for ADH1 8, 2027, with Priority U.S. launch upon FDA Review; MAA submitted approval to EMA First participant dosed Encaleret for chronic in RECLAIM-HP, Topline data hypoparathyroidism registrational Phase 3 anticipated early 2028 study Oral infigratinib for Enrolling additional Initiation of dosing in hypochondroplasia dose cohorts for Phase additional dose cohorts 2 study Depleter (BBP-717) for Development candidate Submit IND to the FDA ATTR-CM nomination in 2027
“I’m heartened by how consistently the evidence for acoramidis keeps pointing in the same direction,” said Neil Kumar, Chief Executive Officer of BridgeBio. “This quarter we added two more large real-world comparisons to a growing body of data showing acoramidis outperforming tafamidis on the outcomes that matter most to patients: survival and hospitalizations. This is exactly what you would expect from the only near-complete stabilizer on the market, and it is deeply gratifying to see it borne out in the real world. This is also a particularly special moment for the company. Three PDUFA dates fall within the next seven months, each with the potential to be a first for communities that have waited far too long: BBP-418 for LGMD2I/R9, where no approved therapy exists; infigratinib as the first oral option for achondroplasia; and encaleret for ADH1, which has never had a therapy of its own.”
The third quarter total revenues, net totaled $353.2 million, comprised of $253.2 million of U.S. Attruby net product revenue, $0.1 million of Rest of World Attruby net product revenue, $20.5 million from royalty revenue, and $79.3 million in license and services revenue.
“Attruby delivered another quarter of sequential growth, driven by continued gains in first-line share, and the real-world evidence emerging across independent datasets continues to reinforce its position as the stabilizer of choice,” said Matt Outten, Chief Commercial Officer of BridgeBio. “This is a pivotal moment for BridgeBio as we stand weeks away from the potential approval of BBP-418, the first and only treatment for LGMD2I/R9, followed by infigratinib in February and encaleret in May. Our field teams for all three programs are hired and ready to serve these communities from day one.” 2 Pipeline Updates:
• Acoramidis significantly reduced the risk of early clinical worsening versus tafamidis in the first peer-reviewed, contemporary real-world comparative effectiveness study of TTR stabilizers, published in Cardiology and Therapy 1 using U.S. claims data, with a statistically and clinically significant 34% reduction in composite clinical worsening (HR 0.66; p=0.046) and a 43% reduction in diuretic intensification (HR 0.57; p=0.021). Separation in clinical outcomes emerged within weeks of treatment initiation and increased over time.
• BridgeBio presented 2 an independent, real-world, propensity score-matched analysis of 2,684 individuals with ATTR-CM from a contemporary population in the Epic COSMOS U.S. electronic health record database at the Heart Failure Society of America Annual Scientific Meeting 2026. Compared with tafamidis, acoramidis was associated with an 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification (HR 0.82; p<0.01), as well as a 27% lower risk of cardiovascular hospitalization, a 27% lower risk of heart failure hospitalization and a 25% lower risk of all- cause hospitalization (all p<0.001).
• These comparative effectiveness findings continue to build on consistent results from several other analyses, including the independent TriNetX propensity score-matched analysis published in JSCAI, the ReplicATTR trial- emulation study, and the anchored matching-adjusted indirect comparison presented at ESC-HF 2026.
• New data at the European Society of Cardiology Congress 2026 provided evidence of a potential reversal of cardiac structural disease progression in ATTR-CM, with serial CMR imaging from ATTRibute-CM and its open-label extension showing clinically meaningful improvement in left ventricular systolic function in 54% of acoramidis-treated participants versus 20% of placebo-treated participants at Month 30 and in 53% of continuous-acoramidis participants at Month 42 in a completer analysis. Participants treated with acoramidis also gained an unprecedented 65 additional days alive and out of the hospital by Month 36. Month 54 data across variant ATTR-CM subgroups, published simultaneously in the European Journal of Heart Failure 3 , showed a more than two-fold mortality difference favoring continuous acoramidis within the p.Val142Ile subgroup.
• Building on the ESC data, BridgeBio dosed the first participant in ASCEND- ATTR. This Phase 3b/4 study is designed to determine whether acoramidis is associated with sustained improvement in cardiac structure, function, and amyloid burden, as measured by cardiac MRI and echocardiography over 36 months.
• Additional data on the benefit of acoramidis for individuals with ATTR-CM will be shared at the upcoming American Heart Association (AHA) 2026 Scientific Sessions.
BBP-418 – Glycosylation substrate for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9):
• BridgeBio believes BBP-418 is positioned to become the first and only approved therapy for individuals living with LGMD2I/R9, addressing a significant unmet need in this disease and potentially representing the first approval of a therapy for any form of LGMD.
• On May 27, 2026, the FDA accepted the Company’s New Drug Application (NDA) for BBP-418 and granted Priority Review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026. No advisory committee meeting is currently planned.
2 https://investor.bridgebio.com/news/news-details/2026/Acoramidis-Associated- with-Significantly-Improved-Clinical-Outcomes-Versus-Tafamidis-in-ATTR-CM-in-an- Independent-Real-World-Study-of-U-S--Electronic-Health-Records/default.aspx
3 https://academic.oup.com/eurjhf/advance- article/doi/10.1093/ejhf/xuag258/8770437 3 • BridgeBio presented 4 new exploratory cardiac data from the Phase 3 FORTIFY trial of BBP-418 in LGMD2I/R9 at the World Muscle Society (WMS) Congress 2026. Cardiac involvement is an important driver of morbidity and mortality in LGMD2I/R9 and an area of significant unmet need. At Month 12, 100% of BBP-418-treated participants with baseline elevated high-sensitivity troponin I, a blood marker of heart muscle injury, returned to the normal range, compared with 40% on placebo (p=0.0248). In addition, 54% of BBP-418-treated participants had stable or improved heart pumping function (LVEF), compared with 25% on placebo (p=0.0262). These results demonstrate potential to ameliorate cardiac dysfunction by targeting the disease at its source with BBP-418 treatment.
• Additionally, a poster shared 5 at the WMS Congress 2026 showed that BBP-418 increased mean glycosylated αDG above asymptomatic carrier levels by Month 12, suggesting it can restore glycosylated αDG to unaffected levels. Together with functional improvement from baseline rather than stabilization, this pattern of biomarker normalization is consistent with the potential for BBP-418 to be a disease-modifying therapy.
• About one month from the PDUFA date, the Company has identified more than 500 unique patients with LGMD2I/R9 in the U.S. through claims, genetic testing, and account profiling. About 70% of individuals living with LGMD2I/R9 receive care through the Muscular Dystrophy Association (MDA) Care Center Network. Since entering the field in August 2026, the Company’s Neuromuscular Account Managers have reached more than 70% of MDA centers and are expected to reach at least 90% of these centers by the PDUFA date.
• After multiple positive, highly collaborative interactions with national health authorities in the European Union (EU), the Company intends to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the first half of 2028. The MAA will be based on the final analysis of the Phase 3 FORTIFY study at Month 36, with topline results expected late 2027/early 2028. Europe has the highest prevalence of LGMD2I/R9 globally, with more than 4,000 patients, due to a founder mutation most often found in people of Northern European ancestry.
• To raise disease awareness and increase genetic testing, BridgeBio launched Type Hype, a patient-facing campaign that encourages people with suspected LGMD to ask their doctor about genetic testing. The Company also took part in a Lifetime feature, along with Kelly Brazzo, CEO and Founder of CureLGMD2i Foundation, on The Balancing Act for LGMD Awareness Day.
• The Company intends to initiate clinical studies of BBP-418 in LGMD2I/R9 for individuals who are less than 12 years of age in the first half of 2027, and in LGMD2M/R13 and LGMD2U/R20 in the near future.
• BridgeBio believes oral infigratinib is positioned to become the first approved oral therapy and a potential best-in-class option for children living with achondroplasia and hypochondroplasia.
• The FDA accepted the Company’s NDA for oral infigratinib and granted Priority Review, assigning a PDUFA target action date of February 4, 2027. Oral infigratinib has received Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations from the FDA, and Orphan Drug Designation from both the FDA and the EMA. Oral infigratinib is the only therapeutic option in development for achondroplasia to hold Breakthrough Therapy Designation.
• The Company submitted an MAA to the EMA for oral infigratinib in achondroplasia, which is now under review, with potential EU approval in the second half of 2027.
4 https://investor.bridgebio.com/news/news-details/2026/BBP-418-Demonstrates- Potential-to-Be-Disease-Modifying-Therapy-Restoring-Cardiac-and-Disease-Markers- to-Unaffected-Levels/default.aspx
5 https://s205.q4cdn.com/224494602/files/doc_presentations/2026/Oct/02/BBIO- BBP-418-WMS-2026-aDG-in-FKRPCarriers-of-LGMD2I-R9.pdf 4 • BridgeBio presented 6 new exploratory data from the Phase 3 PROPEL 3 trial at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, showing favorable trends in health outcomes beyond height for children living with achondroplasia. Over 52 weeks, children treated with oral infigratinib had a 38% lower rate of ear infections (otitis media) than placebo, and sleep apnea measures stayed stable compared with a 49% increase on placebo. Longer-term PROPEL program data showed sustained gains in growth and body proportionality through three years of treatment, with no new safety signals.
• Additionally, BridgeBio shared 7 a poster at the ASBMR 2026 Annual Meeting, featuring data showing a lack of peripheral FGFR1 inhibition at clinically relevant infigratinib exposures, supporting the safety profile observed in children with achondroplasia in the PROPEL clinical program.
• BridgeBio fully staffed its U.S. field team for oral infigratinib. The team brings deep experience across growth disorders, including achondroplasia, rare genetic conditions, and competitive launches.
• The Company is actively enrolling participants for its achondroplasia program from birth to under 3 years of age.
• In hypochondroplasia, the Phase 2/3 ACCEL study is expanding to higher doses to find the optimal dose, supported by safety data from PROPEL 3 and PROPEL OLE.
Encaleret – Calcium-sensing receptor (CaSR) antagonist for autosomal dominant hypocalcemia type 1 (ADH1) and chronic hypoparathyroidism:
• BridgeBio believes encaleret is positioned to become the first approved therapy specifically indicated for individuals living with ADH1, in both the U.S. and EU.
• The FDA accepted the Company’s NDA for encaleret and granted Priority Review, assigning a PDUFA target action date of May 8, 2027. No advisory committee meeting is currently planned.
• BridgeBio submitted an MAA to the EMA for the use of encaleret in ADH1, which is now under review, with potential EU approval in the second half of 2027.
• New Phase 3 CALIBRATE data presented at the American Society of Nephrology Kidney Week 2026 showed 8 that encaleret was associated with a significant increase in kidney function (eGFR) at Week 24 compared with conventional therapy (+11 vs. +3 mL/min/1.73m²; p<0.05), suggesting that encaleret may preserve or improve kidney function in an ADH1 patient population that is at risk of kidney complications when managed with conventional therapy.
• Additionally, at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, new Phase 3 CALIBRATE data showed 9 encaleret increased bone turnover, based on its action to recover the body’s own PTH production, and 100% of encaleret participants reported improvement in at least one ADH1 symptom (vs. 46% on standard of care).
• The U.S. field team dedicated to encaleret has been trained and deployed, and continues to expand diagnosis through disease state education and no-cost genetic testing. There are now >600 genetically confirmed patients identified, up from approximately 500 last quarter.
• CALIBRATE-PEDS, the registrational Phase 2/3 study of encaleret in pediatric ADH1, is ongoing and has completed enrollment in the first of four cohorts (adolescents 12 to 17 years of age).
6 https://investor.bridgebio.com/news/news-details/2026/Oral-Infigratinib-Shows- Meaningful-Benefits-Beyond-Growth-Within-52-Weeks-in-Children-with- Achondroplasia-in-the-Phase-3-PROPEL-3-Trial/default.aspx
7 https://cdn.sanity.io/files/fcrea868/production/5e74345c1aaf6a6d0fad7f29253e02 727b05948c.pdf
8 https://s205.q4cdn.com/224494602/files/doc_presentations/2026/Oct/24/BBIO- Encaleret-ASN-2026-CALIBRATE-renal-Sayer.pdf
9 https://investor.bridgebio.com/news/news-details/2026/Encaleret-Increased- Bone-Turnover-and-Improved-Participant-Reported-Symptoms-in-the- Phase-3-CALIBRATE-Trial-in-ADH1/default.aspx 5 • The first participant was dosed in RECLAIM-HP, the registrational Phase 3 study of encaleret in chronic hypoparathyroidism. Topline results from the study are anticipated in early 2028. Chronic hypoparathyroidism affects approximately 200,000 patients in the U.S. and EU and represents a substantial expansion of the encaleret opportunity beyond ADH1. Encaleret is the only oral therapy in development being evaluated to normalize both blood and urine calcium in this population.
• BridgeBio nominated BBP-717 as a development candidate. BBP-717 is a next- generation monoclonal antibody designed to deplete amyloid deposits in patients with ATTR-CM. The Company plans to submit an Investigational New Drug (IND) application to the FDA in 2027.
• BBP-717 builds on BridgeBio’s leadership in ATTR-CM and is designed to complement near-complete TTR stabilization by clearing existing amyloid deposits. 6 Financial Updates:
Cash, cash equivalents and marketable securities totaled $1.5 billion and $587.5 million as of September 30, 2026 and December 31, 2025, respectively.
Total revenues, net for the three months ended September 30, 2026 were $353.2 million compared to $120.7 million for the same period in 2025. The $232.5 million increase was primarily driven by a $145.2 million increase in Attruby net product revenue, a $71.1 million increase in license and services revenue primarily due to recognition of a $75.0 million sales milestone under the Bayer License Agreement achieved during the third quarter of 2026, and a $16.2 million increase in royalty revenue primarily earned from net product sales of BEYONTTRA in the EU and Japan.
Total revenues, net for the nine months ended September 30, 2026 were $791.4 million compared to $347.9 million for the same period in 2025. The $443.5 million increase was primarily driven by a $440.0 million increase in Attruby net product revenue and a $39.3 million increase in royalty revenue primarily earned from net product sales of BEYONTTRA in the EU and Japan. These increases were partially offset by a $35.8 million decrease in license and services revenue. This decrease was primarily due to recognition of $105.0 million of regulatory milestone-related revenues during the nine months ended September 30, 2025, partially offset by recognition of a $75.0 million sales milestone under the Bayer License Agreement achieved during the third quarter of 2026.
7 Total operating costs and expenses for the three months ended September 30, 2026 were $364.8 million, compared to $265.9 million for the same period in 2025. The $98.9 million increase was primarily driven by a $63.2 million increase in selling, general and administrative (SG&A) expenses, reflecting continued investment in both the ongoing commercialization of Attruby and the pre- commercial activities for BridgeBio's late-stage product candidates, a $30.6 million increase in research and development (R&D) expenses to support the development of late-stage product candidates, and a $13.9 million increase in total cost of revenues primarily due to higher sales volume of Attruby.
Total operating costs and expenses for the nine months ended September 30, 2026 were $1.0 billion, compared to $731.7 million for the same period in 2025. The $284.3 million increase was primarily driven by a $177.9 million increase in SG&A expenses, reflecting continued investment in both the ongoing commercialization of Attruby and the pre-commercial activities for BridgeBio's late-stage product candidates, an $84.1 million increase in R&D expenses to support the development of late-stage product candidates, and a $32.6 million increase in total cost of revenues primarily due to higher sales volume of Attruby.
Stock-based compensation expenses included in operating costs and expenses for the three months ended September 30, 2026 were $39.9 million, of which $24.6 million, $14.9 million, and $0.4 million were included in SG&A expenses, R&D expenses, and cost of goods sold, respectively. Stock-based compensation expenses included in operating costs and expenses for the same period in 2025 were $35.3 million, of which $21.9 million , $12.3 million, $0.7 million, and $0.4 million were included in SG&A expenses, R&D expenses, restructuring, impairment, and related charges, and cost of goods sold, respectively.
Stock-based compensation expenses included in operating costs and expenses for the nine months ended September 30, 2026 were $117.7 million, of which $73.2 million, $42.5 million, and $2.0 million were included in SG&A expenses, R&D expenses, and cost of goods sold, respectively. Stock-based compensation expenses included in operating costs and expenses for the same period in 2025 were $102.0 million, of which $63.1 million , $37.6 million, $0.7 million, and $0.6 million were included in SG&A expenses, R&D expenses, restructuring, impairment, and related charges, and cost of goods sold, respectively.
Total other income (expense), net for the three and nine months ended September 30, 2026, was $(47.6) million and $(157.0) million, respectively, compared to $(41.3) million and $(153.9) million, respectively, for the same periods in 2025.
The increase in total other income (expense), net of $6.3 million for the three months ended September 30, 2026, compared to the same period in 2025 was primarily driven by a $7.8 million decrease in nonrecurring noncash income from an equity method investment recognized in 2025, a $5.9 million increase in noncash interest expense related to deferred royalty obligations, and a $4.2 million decrease in other income resulting from changes in the valuation of the embedded derivative liability component of our deferred royalty obligation. These changes were partially offset by an $8.5 million decrease in net loss from equity method investments and a $6.9 million increase in interest income. 8 The increase in total other income (expense), net of $3.1 million for the nine months ended September 30, 2026, compared to the same period in 2025 was primarily driven by a $37.0 million increase in noncash interest expense related to deferred royalty obligations, a $7.8 million decrease in nonrecurring noncash income from an equity method investment recognized in 2025, a $4.9 million decrease in net gains on foreign currency transactions, and a $4.0 million decrease in other income resulting from changes in the valuation of the embedded derivative liability component of our deferred royalty obligation. These changes were partially offset by a $21.2 million decrease in loss on extinguishment of debt recognized in the first quarter of 2025, a $19.5 million decrease in net loss from equity method investments, and a $10.5 million increase in interest income. Net Loss Attributable to Common Stockholders of BridgeBio and Net Loss per Share For the three and nine months ended September 30, 2026, the Company recorded a net loss attributable to common stockholders of BridgeBio of $83.0 million and $399.3 million, respectively, compared to $182.7 million and $532.1 million, respectively, for the same periods in 2025.
For the three and nine months ended September 30, 2026, the Company reported a net loss per share of $0.42 and $2.04, respectively, compared to $0.95 and $2.79, respectively, for the same periods in 2025.
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -Unaudited -1 Assets Cash, cash equivalents and marketable $ 1,538,855 $ 587,482 securities Accounts receivable, net 375,089 139,444 Inventories 59,718 26,753 Prepaid expenses and other current 70,944 44,070 assets Total current assets 2,044,606 797,749 Equity method investments 47,783 79,972 Property and equipment, net 5,042 5,366 Operating lease 15,746 8,149 right-of-use assets Intangible assets, net 25,923 28,077 Other assets 22,686 16,712 Total assets $ 2,161,786 $ 936,025 Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders' Deficit Accounts payable $ 88,258 $ 36,228 Operating lease liabilities, current 1,987 6,192 portion Deferred revenue, current 4,744 7,190 portion 2027 Notes, net 548,430 — Accrued and other current 333,818 238,361 liabilities Total current liabilities 977,237 287,971 Operating lease liabilities, net of 14,645 3,811 current portion Deferred revenue, net of 8,968 13,080 current portion 2027 Notes, net — 547,015 2029 Notes, net 742,437 740,890 2031 Notes, net 566,013 564,565 2033 Notes, net 620,533 — Deferred royalty 884,053 855,030 obligations, net Other long-term liabilities 1,405 244 Redeemable convertible noncontrolling -1,363 -570 interests Series A preferred stock 942,478 — Common stock 207 202 Treasury stock, at cost -580,775 -323,276 Additional paid-in capital 2,170,006 2,057,646 Accumulated other comprehensive income -95 12 (loss) Accumulated deficit -4,194,163 -3,821,194 Noncontrolling interests 10,200 10,599 Total liabilities, redeemable convertible noncontrolling $ 2,161,786 $ 936,025 interests and stockholders' deficit
Nine Months Ended September 30, 2026 Operating activities: (Unaudited) 2025 ────────────────────────────────────────────────────────────────────────────── Net loss $ -382,942 $ -538,303 Adjustments to reconcile net loss to net cash used in operating activities: Noncash interest expense on deferred 123,500 86,460 royalty obligations Stock-based 117,171 98,385 compensation Net loss from equity 32,030 51,579 method investments Change in fair value of the embedded derivative associated -7,098 -11,062 with the deferred royalty obligation Amortization of debt discount and 5,670 4,515 issuance costs Depreciation and 3,308 3,999 amortization Noncash lease expense 4,714 3,443 Loss on extinguishment — 21,155 of debt Noncash income from an equity method — -7,769 investment Other noncash 2,233 -1,217 adjustments, net Changes in operating assets and liabilities: Accounts receivable, -235,646 -111,796 net Inventories -35,641 -23,356 Prepaid expenses and other current -26,872 -17,527 assets Other assets -5,849 568 Accounts payable 51,993 9,084 Accrued compensation -9,049 3,212 and benefits Accrued research and development 13,583 347 liabilities Operating lease -5,494 -4,757 liabilities Deferred revenue -6,558 -9,480 Other liabilities 48,397 53,030 Net cash used in -312,550 -389,490 operating activities Investing activities: Purchases of -63,937 -10,876 marketable securities Maturities of 76,500 8,000 marketable securities Proceeds from special cash dividends received from an — 2,302 investment in equity securities Payment for intangible — -8,495 assets Purchases of property -802 -1,064 and equipment Net cash provided by (used in) investing 11,761 -10,133 activities Financing activities: Proceeds from issuance 632,500 — of 2033 Notes Issuance costs and discounts associated -13,227 — with 2033 Notes Proceeds from issuance — 575,000 of 2031 Notes Issuance costs and discounts associated — -12,034 with 2031 Notes Repayment of term — -459,000 loans Proceeds from royalty obligation under Royalty Purchase — 300,000 Agreement (as described in Note 9) Issuance costs associated with royalty — -3,010 obligation under Royalty Purchase Agreement Repayments of deferred royalty -62,507 -6,896 obligations Proceeds from issuance of preferred 933,900 — stock Issuance costs associated with -1,342 — preferred stock Payment of preferred -2,694 — stock dividends Repurchase of common -252,502 -48,276 stock Proceeds from stock option exercises, 33,712 14,523 net of repurchases Proceeds from common stock issuances 9,728 6,414 under ESPP
Repurchase of RSU shares to satisfy tax -13,431 -6,796 withholding Transactions with noncontrolling — 1,550 interests Net cash provided by financing 1,264,137 361,475 activities Net increase (decrease) in cash, cash 963,348 -38,148 equivalents, and restricted cash Cash, cash equivalents, and restricted 572,140 683,244 cash at beginning of period Cash, cash equivalents, and restricted $ 1,535,488 $ 645,096 cash at end of period
Supplemental Nine Months Ended Disclosure of Cash September 30, Flow 2026 Information: (Unaudited) 2025 ────────────────────────────────────────────────────────────────────────────── Cash paid for interest $ 43,135 $ 43,670 Supplemental Disclosures of Noncash Investing and Financing Information: Accretion of preferred $ 9,920 $ — stock Accrued cash dividends on preferred $ 13,679 $ — stock Accrual for repurchase $ 4,997 $ — of common stock Transfers to noncontrolling $ -8,765 $ -4,734 interests Reconciliation of Cash, Cash Equivalents and Restricted Cash:
Cash and cash $ 1,533,363 $ 642,951 equivalents Restricted cash — Included in “Prepaid 550 126 expenses and other current assets” Restricted cash — Included in “Other 1,575 2,019 assets” Total cash, cash equivalents and restricted cash at end of periods shown on $ 1,535,488 $ 645,096 the condensed consolidated statements of cash flows
BridgeBio will host a conference call and webcast to discuss third quarter financial results today, October 29, 2026, at 4:30 pm ET. This event can be accessed at https://events.q4inc.com/attendee/463906479 or by visiting the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com . A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR- CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively). 14
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements, including express and implied statements relating to the continued commercial success and market potential of Attruby/Beyonttra (acoramidis); the Company’s expectations regarding timing of regulatory submissions and target action dates, approvals and commercial launches in the U.S. and Europe, including for BBP-418 for LGMD2I/R9, encaleret for ADH1, and oral infigratinib for achondroplasia; the Company’s expectations regarding the timing and outcome of pre-commercial activities, including activities designed to support three potential launches; the timing of the Company’s clinical trials, milestones and expected updates for its various programs and pipeline; the safety and the potential benefits of the Company’s product and product candidates; the Company’s anticipated presentations of data; and the Company’s belief that its cash, cash equivalents and marketable securities will enable the Company to fund its three potential launches and expansion indications across its pipeline. Such statements reflect the Company’s current views about the Company’s plans, intentions, expectations and strategies, which are based on the information currently available to it and on assumptions the Company has made. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s preclinical studies and clinical trials not being indicative of final data, the potential size of the target patient populations the Company’s product candidates are designed to treat not being as large as anticipated, the design and success of ongoing and planned clinical trials, future regulatory filings, approvals and/or sales, despite having ongoing and future interactions with the FDA or other regulatory agencies to discuss potential paths to registration for the Company’s product candidates, the FDA or such other regulatory agencies not agreeing with the Company’s regulatory approval strategies, components of the Company’s filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted, the Company’s pre-commercial activities, commercial launches or operational execution not occurring on anticipated timelines or not supporting planned launches as expected, real-world experience with Attruby/Beyonttra not being consistent with observed biochemical differentiation or not translating into differentiated clinical, commercial or market outcomes, the continuing success of the Company’s collaborations, the Company’s ability to obtain additional funding, including through less dilutive sources of capital than equity financings, potential volatility in 15 the Company’s share price, the Company’s share repurchase program being modified, suspended or discontinued, or share repurchases not delivering the anticipated benefits or proving to be a more attractive use of capital than other alternatives, the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Full text with the tables
Exhibit 99.1
BridgeBio Reports Third Quarter 2026
Financial Results and Corporate Updates
- $353.2 million in total third quarter revenues, primarily comprised of $253.2
million of U.S. Attruby net product revenue (up approximately $31 million
sequentially and $145 million year over year). Loss from operations was $11.6
million, driven by increased revenue and a one-time $75.0 million BEYONTTRA
sales milestone from Bayer. Cash, cash equivalents and marketable securities
were $1.5 billion as of September 30, 2026, fully funding all three launches and
expansion indications
- Attruby growth was again led by the treatment-naïve segment, with both the
number of newly diagnosed patients starting treatment and Attruby's share of
those starts increasing
- Real-world evidence continues to differentiate acoramidis from tafamidis on
outcomes that matter to patients, physicians, and payers: (i) an independent
Epic COSMOS analysis of 2,684 patients found an 18% lower risk of death,
hospitalization, new atrial fibrillation or diuretic escalation (p<0.01) with a
25% lower risk of hospitalization with acoramidis (p<0.001); (ii) the first
peer-reviewed real-world comparison of TTR stabilizers found 34% less clinical
worsening with acoramidis (p=0.046)
- Cardiac MRI from ATTRibute-CM and its extension showed evidence of potential
reversal of structural damage and functional decline through 42 months for
patients on acoramidis, with up to half of completers achieving clinically
meaningful improvement in heart function. The first participant was dosed in
ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with
Attruby
- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority
Review. Launch preparation is well advanced, with 70% of patients concentrated
at MDA Care Centers, over 70% of which the field team has reached with a 90%
target by PDUFA. Based on interactions with EU national health authorities, the
Company intends to submit an MAA to the EMA in the first half of 2028
- Oral infigratinib for achondroplasia has a February 4, 2027 PDUFA date, with
Priority Review. The MAA is now under EMA review with potential EU approval in
the second half of 2027. Launch preparation is well advanced, with the U.S.
field team fully staffed. In hypochondroplasia, the Phase 2/3 ACCEL study is
expanding to higher doses to find the optimal dose, supported by safety data
from PROPEL 3 and PROPEL OLE
- Encaleret for ADH1 has a May 8, 2027 PDUFA date, with Priority Review, and the
MAA is under EMA review with potential EU approval in the second half of 2027.
Launch preparation is well advanced, with >600 genetically confirmed patients
identified, up from approximately 500 last quarter, and the U.S. field team is
fully deployed
- The first participant was dosed in RECLAIM-HP, the Phase 3 study for encaleret
in chronic hypoparathyroidism. Topline data are expected in early 2028,
representing a potential second indication in an estimated population of 200,000
patients in the U.S. and EU
PALO ALTO, Calif., October 29, 2026 --
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a
commercial-stage, multi-product biopharmaceutical company focused on developing
medicines for genetic conditions, announced today its financial results for the
third quarter ended September 30, 2026, and provided an update on Attruby’s
commercial progress.
1
Pipeline Overview:
Status
Approved in U.S., EU,
Japan, Switzerland,
Brazil, U.K., and
Australia
PDUFA date set for Next expected milestone
November 27, 2026, with New data to be shared
Program Priority Review at AHA 2026
Acoramidis for ATTR-CM PDUFA date set for U.S. launch upon FDA
BBP-418 for LGMD2I/R9 February 4, 2027, with approval
Oral infigratinib for Priority Review; MAA U.S. launch upon FDA
achondroplasia submitted to EMA approval
──────────────────────────────────────────────────────────────────────────────
PDUFA date set for May
Encaleret for ADH1 8, 2027, with Priority U.S. launch upon FDA
Review; MAA submitted approval
to EMA
First participant dosed
Encaleret for chronic in RECLAIM-HP, Topline data
hypoparathyroidism registrational Phase 3 anticipated early 2028
study
Oral infigratinib for Enrolling additional Initiation of dosing in
hypochondroplasia dose cohorts for Phase additional dose cohorts
2 study
Depleter (BBP-717) for Development candidate Submit IND to the FDA
ATTR-CM nomination in 2027
“I’m heartened by how consistently the evidence for acoramidis keeps pointing in
the same direction,” said Neil Kumar, Chief Executive Officer of BridgeBio.
“This quarter we added two more large real-world comparisons to a growing body
of data showing acoramidis outperforming tafamidis on the outcomes that matter
most to patients: survival and hospitalizations. This is exactly what you would
expect from the only near-complete stabilizer on the market, and it is deeply
gratifying to see it borne out in the real world. This is also a particularly
special moment for the company. Three PDUFA dates fall within the next seven
months, each with the potential to be a first for communities that have waited
far too long: BBP-418 for LGMD2I/R9, where no approved therapy exists;
infigratinib as the first oral option for achondroplasia; and encaleret for
ADH1, which has never had a therapy of its own.”
Commercial Updates:
The third quarter total revenues, net totaled $353.2 million, comprised of
$253.2 million of U.S. Attruby net product revenue, $0.1 million of Rest of
World Attruby net product revenue, $20.5 million from royalty revenue, and $79.3
million in license and services revenue.
“Attruby delivered another quarter of sequential growth, driven by continued
gains in first-line share, and the real-world evidence emerging across
independent datasets continues to reinforce its position as the stabilizer of
choice,” said Matt Outten, Chief Commercial Officer of BridgeBio. “This is a
pivotal moment for BridgeBio as we stand weeks away from the potential approval
of BBP-418, the first and only treatment for LGMD2I/R9, followed by infigratinib
in February and encaleret in May. Our field teams for all three programs are
hired and ready to serve these communities from day one.”
2
Pipeline Updates:
Attruby (acoramidis) – First and only near-complete (≥90%) transthyretin (TTR)
stabilizer for treatment of transthyretin amyloid cardiomyopathy (ATTR-CM):
• Acoramidis significantly reduced the risk of early clinical worsening versus
tafamidis in the first peer-reviewed, contemporary real-world comparative
effectiveness study of TTR stabilizers, published in Cardiology and Therapy 1
using U.S. claims data, with a statistically and clinically significant 34%
reduction in composite clinical worsening (HR 0.66; p=0.046) and a 43% reduction
in diuretic intensification (HR 0.57; p=0.021). Separation in clinical outcomes
emerged within weeks of treatment initiation and increased over time.
• BridgeBio presented 2 an independent, real-world, propensity score-matched
analysis of 2,684 individuals with ATTR-CM from a contemporary population in the
Epic COSMOS U.S. electronic health record database at the Heart Failure Society
of America Annual Scientific Meeting 2026. Compared with tafamidis, acoramidis
was associated with an 18% lower risk of a composite of death, all-cause
hospitalization, new-onset atrial fibrillation, and diuretic intensification (HR
0.82; p<0.01), as well as a 27% lower risk of cardiovascular hospitalization, a
27% lower risk of heart failure hospitalization and a 25% lower risk of all-
cause hospitalization (all p<0.001).
• These comparative effectiveness findings continue to build on consistent
results from several other analyses, including the independent TriNetX
propensity score-matched analysis published in JSCAI, the ReplicATTR trial-
emulation study, and the anchored matching-adjusted indirect comparison
presented at ESC-HF 2026.
• New data at the European Society of Cardiology Congress 2026 provided evidence
of a potential reversal of cardiac structural disease progression in ATTR-CM,
with serial CMR imaging from ATTRibute-CM and its open-label extension showing
clinically meaningful improvement in left ventricular systolic function in 54%
of acoramidis-treated participants versus 20% of placebo-treated participants at
Month 30 and in 53% of continuous-acoramidis participants at Month 42 in a
completer analysis. Participants treated with acoramidis also gained an
unprecedented 65 additional days alive and out of the hospital by Month 36.
Month 54 data across variant ATTR-CM subgroups, published simultaneously in the
European Journal of Heart Failure 3 , showed a more than two-fold mortality
difference favoring continuous acoramidis within the p.Val142Ile subgroup.
• Building on the ESC data, BridgeBio dosed the first participant in ASCEND-
ATTR. This Phase 3b/4 study is designed to determine whether acoramidis is
associated with sustained improvement in cardiac structure, function, and
amyloid burden, as measured by cardiac MRI and echocardiography over 36 months.
• Additional data on the benefit of acoramidis for individuals with ATTR-CM will
be shared at the upcoming American Heart Association (AHA) 2026 Scientific
Sessions.
BBP-418 – Glycosylation substrate for limb-girdle muscular dystrophy type 2I/R9
(LGMD2I/R9):
• BridgeBio believes BBP-418 is positioned to become the first and only approved
therapy for individuals living with LGMD2I/R9, addressing a significant unmet
need in this disease and potentially representing the first approval of a
therapy for any form of LGMD.
• On May 27, 2026, the FDA accepted the Company’s New Drug Application (NDA) for
BBP-418 and granted Priority Review, assigning a Prescription Drug User Fee Act
(PDUFA) target action date of November 27, 2026. No advisory committee meeting
is currently planned.
1 https://link.springer.com/article/10.1007/s40119-026-00476-2
2 https://investor.bridgebio.com/news/news-details/2026/Acoramidis-Associated-
with-Significantly-Improved-Clinical-Outcomes-Versus-Tafamidis-in-ATTR-CM-in-an-
Independent-Real-World-Study-of-U-S--Electronic-Health-Records/default.aspx
3 https://academic.oup.com/eurjhf/advance-
article/doi/10.1093/ejhf/xuag258/8770437
3
• BridgeBio presented 4 new exploratory cardiac data from the Phase 3 FORTIFY
trial of BBP-418 in LGMD2I/R9 at the World Muscle Society (WMS) Congress 2026.
Cardiac involvement is an important driver of morbidity and mortality in
LGMD2I/R9 and an area of significant unmet need. At Month 12, 100% of
BBP-418-treated participants with baseline elevated high-sensitivity troponin I,
a blood marker of heart muscle injury, returned to the normal range, compared
with 40% on placebo (p=0.0248). In addition, 54% of BBP-418-treated participants
had stable or improved heart pumping function (LVEF), compared with 25% on
placebo (p=0.0262). These results demonstrate potential to ameliorate cardiac
dysfunction by targeting the disease at its source with BBP-418 treatment.
• Additionally, a poster shared 5 at the WMS Congress 2026 showed that BBP-418
increased mean glycosylated αDG above asymptomatic carrier levels by Month 12,
suggesting it can restore glycosylated αDG to unaffected levels. Together with
functional improvement from baseline rather than stabilization, this pattern of
biomarker normalization is consistent with the potential for BBP-418 to be a
disease-modifying therapy.
• About one month from the PDUFA date, the Company has identified more than 500
unique patients with LGMD2I/R9 in the U.S. through claims, genetic testing, and
account profiling. About 70% of individuals living with LGMD2I/R9 receive care
through the Muscular Dystrophy Association (MDA) Care Center Network. Since
entering the field in August 2026, the Company’s Neuromuscular Account Managers
have reached more than 70% of MDA centers and are expected to reach at least 90%
of these centers by the PDUFA date.
• After multiple positive, highly collaborative interactions with national
health authorities in the European Union (EU), the Company intends to submit a
Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)
in the first half of 2028. The MAA will be based on the final analysis of the
Phase 3 FORTIFY study at Month 36, with topline results expected late 2027/early
2028. Europe has the highest prevalence of LGMD2I/R9 globally, with more than
4,000 patients, due to a founder mutation most often found in people of Northern
European ancestry.
• To raise disease awareness and increase genetic testing, BridgeBio launched
Type Hype, a patient-facing campaign that encourages people with suspected LGMD
to ask their doctor about genetic testing. The Company also took part in a
Lifetime feature, along with Kelly Brazzo, CEO and Founder of CureLGMD2i
Foundation, on The Balancing Act for LGMD Awareness Day.
• The Company intends to initiate clinical studies of BBP-418 in LGMD2I/R9 for
individuals who are less than 12 years of age in the first half of 2027, and in
LGMD2M/R13 and LGMD2U/R20 in the near future.
Oral infigratinib – FGFR3 inhibitor for achondroplasia and hypochondroplasia:
• BridgeBio believes oral infigratinib is positioned to become the first
approved oral therapy and a potential best-in-class option for children living
with achondroplasia and hypochondroplasia.
• The FDA accepted the Company’s NDA for oral infigratinib and granted Priority
Review, assigning a PDUFA target action date of February 4, 2027. Oral
infigratinib has received Breakthrough Therapy, Fast Track, and Rare Pediatric
Disease Designations from the FDA, and Orphan Drug Designation from both the FDA
and the EMA. Oral infigratinib is the only therapeutic option in development for
achondroplasia to hold Breakthrough Therapy Designation.
• The Company submitted an MAA to the EMA for oral infigratinib in
achondroplasia, which is now under review, with potential EU approval in the
second half of 2027.
4 https://investor.bridgebio.com/news/news-details/2026/BBP-418-Demonstrates-
Potential-to-Be-Disease-Modifying-Therapy-Restoring-Cardiac-and-Disease-Markers-
to-Unaffected-Levels/default.aspx
5 https://s205.q4cdn.com/224494602/files/doc_presentations/2026/Oct/02/BBIO-
BBP-418-WMS-2026-aDG-in-FKRPCarriers-of-LGMD2I-R9.pdf
4
• BridgeBio presented 6 new exploratory data from the Phase 3 PROPEL 3 trial at
the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026,
showing favorable trends in health outcomes beyond height for children living
with achondroplasia. Over 52 weeks, children treated with oral infigratinib had
a 38% lower rate of ear infections (otitis media) than placebo, and sleep apnea
measures stayed stable compared with a 49% increase on placebo. Longer-term
PROPEL program data showed sustained gains in growth and body proportionality
through three years of treatment, with no new safety signals.
• Additionally, BridgeBio shared 7 a poster at the ASBMR 2026 Annual Meeting,
featuring data showing a lack of peripheral FGFR1 inhibition at clinically
relevant infigratinib exposures, supporting the safety profile observed in
children with achondroplasia in the PROPEL clinical program.
• BridgeBio fully staffed its U.S. field team for oral infigratinib. The team
brings deep experience across growth disorders, including achondroplasia, rare
genetic conditions, and competitive launches.
• The Company is actively enrolling participants for its achondroplasia program
from birth to under 3 years of age.
• In hypochondroplasia, the Phase 2/3 ACCEL study is expanding to higher doses
to find the optimal dose, supported by safety data from PROPEL 3 and PROPEL OLE.
Encaleret – Calcium-sensing receptor (CaSR) antagonist for autosomal dominant
hypocalcemia type 1 (ADH1) and chronic hypoparathyroidism:
• BridgeBio believes encaleret is positioned to become the first approved
therapy specifically indicated for individuals living with ADH1, in both the
U.S. and EU.
• The FDA accepted the Company’s NDA for encaleret and granted Priority Review,
assigning a PDUFA target action date of May 8, 2027. No advisory committee
meeting is currently planned.
• BridgeBio submitted an MAA to the EMA for the use of encaleret in ADH1, which
is now under review, with potential EU approval in the second half of 2027.
• New Phase 3 CALIBRATE data presented at the American Society of Nephrology
Kidney Week 2026 showed 8 that encaleret was associated with a significant
increase in kidney function (eGFR) at Week 24 compared with conventional therapy
(+11 vs. +3 mL/min/1.73m²; p<0.05), suggesting that encaleret may preserve or
improve kidney function in an ADH1 patient population that is at risk of kidney
complications when managed with conventional therapy.
• Additionally, at the American Society for Bone and Mineral Research (ASBMR)
2026 Annual Meeting, new Phase 3 CALIBRATE data showed 9 encaleret increased
bone turnover, based on its action to recover the body’s own PTH production, and
100% of encaleret participants reported improvement in at least one ADH1 symptom
(vs. 46% on standard of care).
• The U.S. field team dedicated to encaleret has been trained and deployed, and
continues to expand diagnosis through disease state education and no-cost
genetic testing. There are now >600 genetically confirmed patients identified,
up from approximately 500 last quarter.
• CALIBRATE-PEDS, the registrational Phase 2/3 study of encaleret in pediatric
ADH1, is ongoing and has completed enrollment in the first of four cohorts
(adolescents 12 to 17 years of age).
6 https://investor.bridgebio.com/news/news-details/2026/Oral-Infigratinib-Shows-
Meaningful-Benefits-Beyond-Growth-Within-52-Weeks-in-Children-with-
Achondroplasia-in-the-Phase-3-PROPEL-3-Trial/default.aspx
7 https://cdn.sanity.io/files/fcrea868/production/5e74345c1aaf6a6d0fad7f29253e02
727b05948c.pdf
8 https://s205.q4cdn.com/224494602/files/doc_presentations/2026/Oct/24/BBIO-
Encaleret-ASN-2026-CALIBRATE-renal-Sayer.pdf
9 https://investor.bridgebio.com/news/news-details/2026/Encaleret-Increased-
Bone-Turnover-and-Improved-Participant-Reported-Symptoms-in-the-
Phase-3-CALIBRATE-Trial-in-ADH1/default.aspx
5
• The first participant was dosed in RECLAIM-HP, the registrational Phase 3
study of encaleret in chronic hypoparathyroidism. Topline results from the study
are anticipated in early 2028. Chronic hypoparathyroidism affects approximately
200,000 patients in the U.S. and EU and represents a substantial expansion of
the encaleret opportunity beyond ADH1. Encaleret is the only oral therapy in
development being evaluated to normalize both blood and urine calcium in this
population.
BBP-717 – Monoclonal antibody depleter for ATTR-CM:
• BridgeBio nominated BBP-717 as a development candidate. BBP-717 is a next-
generation monoclonal antibody designed to deplete amyloid deposits in patients
with ATTR-CM. The Company plans to submit an Investigational New Drug (IND)
application to the FDA in 2027.
• BBP-717 builds on BridgeBio’s leadership in ATTR-CM and is designed to
complement near-complete TTR stabilization by clearing existing amyloid
deposits.
6
Financial Updates:
Cash, Cash Equivalents and Marketable Securities
Cash, cash equivalents and marketable securities totaled $1.5 billion and $587.5
million as of September 30, 2026 and December 31, 2025, respectively.
Total Revenues, Net
Three
Months
Ended Nine
Septem… Months
30, Ended
2026 Septe…
(in 30,
thousa… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net
prod… $ 253,3… $ 108,111 $ 656,382 $ 216,3…
reve…
Lice…
and 79,314 8,311 89,537 125,4…
serv…
reve…
Roya… 20,511 4,278 45,443 6,106
reve…
Total
reve… $ 353,1… $ 120,700 $ 791,362 $ 347,8…
net
Total revenues, net for the three months ended September 30, 2026 were $353.2
million compared to $120.7 million for the same period in 2025. The $232.5
million increase was primarily driven by a $145.2 million increase in Attruby
net product revenue, a $71.1 million increase in license and services revenue
primarily due to recognition of a $75.0 million sales milestone under the Bayer
License Agreement achieved during the third quarter of 2026, and a $16.2 million
increase in royalty revenue primarily earned from net product sales of BEYONTTRA
in the EU and Japan.
Total revenues, net for the nine months ended September 30, 2026 were $791.4
million compared to $347.9 million for the same period in 2025. The $443.5
million increase was primarily driven by a $440.0 million increase in Attruby
net product revenue and a $39.3 million increase in royalty revenue primarily
earned from net product sales of BEYONTTRA in the EU and Japan. These increases
were partially offset by a $35.8 million decrease in license and services
revenue. This decrease was primarily due to recognition of $105.0 million of
regulatory milestone-related revenues during the nine months ended September 30,
2025, partially offset by recognition of a $75.0 million sales milestone under
the Bayer License Agreement achieved during the third quarter of 2026.
Total Operating Costs and Expenses
Three
Months
Ended Nine
Septem… Months
30, Ended
2026 Septe…
(in 30,
thousa… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Total
cost $ 20,450 $ 6,563 $ 45,435 $ 12,855
of
reve…
Rese…
and 143,5… 112,874 419,590 335,5…
deve…
Sell…
gene… 200,8… 137,621 551,011 373,1…
and
admi…
Rest…
impa…
and — 8,841 — 10,216
rela…
char…
Total
oper…
costs $ 364,8… $ 265,899 $ 1,016,… $ 731,7…
and
expe…
7
Total operating costs and expenses for the three months ended September 30, 2026
were $364.8 million, compared to $265.9 million for the same period in 2025. The
$98.9 million increase was primarily driven by a $63.2 million increase in
selling, general and administrative (SG&A) expenses, reflecting continued
investment in both the ongoing commercialization of Attruby and the pre-
commercial activities for BridgeBio's late-stage product candidates, a $30.6
million increase in research and development (R&D) expenses to support the
development of late-stage product candidates, and a $13.9 million increase in
total cost of revenues primarily due to higher sales volume of Attruby.
Total operating costs and expenses for the nine months ended September 30, 2026
were $1.0 billion, compared to $731.7 million for the same period in 2025. The
$284.3 million increase was primarily driven by a $177.9 million increase in
SG&A expenses, reflecting continued investment in both the ongoing
commercialization of Attruby and the pre-commercial activities for BridgeBio's
late-stage product candidates, an $84.1 million increase in R&D expenses to
support the development of late-stage product candidates, and a $32.6 million
increase in total cost of revenues primarily due to higher sales volume of
Attruby.
Stock-based compensation expenses included in operating costs and expenses for
the three months ended September 30, 2026 were $39.9 million, of which $24.6
million, $14.9 million, and $0.4 million were included in SG&A expenses, R&D
expenses, and cost of goods sold, respectively. Stock-based compensation
expenses included in operating costs and expenses for the same period in 2025
were $35.3 million, of which $21.9 million , $12.3 million, $0.7 million, and
$0.4 million were included in SG&A expenses, R&D expenses, restructuring,
impairment, and related charges, and cost of goods sold, respectively.
Stock-based compensation expenses included in operating costs and expenses for
the nine months ended September 30, 2026 were $117.7 million, of which $73.2
million, $42.5 million, and $2.0 million were included in SG&A expenses, R&D
expenses, and cost of goods sold, respectively. Stock-based compensation
expenses included in operating costs and expenses for the same period in 2025
were $102.0 million, of which $63.1 million , $37.6 million, $0.7 million, and
$0.6 million were included in SG&A expenses, R&D expenses, restructuring,
impairment, and related charges, and cost of goods sold, respectively.
Total Other Income (Expense), Net
Total other income (expense), net for the three and nine months ended September
30, 2026, was $(47.6) million and $(157.0) million, respectively, compared to
$(41.3) million and $(153.9) million, respectively, for the same periods in
2025.
The increase in total other income (expense), net of $6.3 million for the three
months ended September 30, 2026, compared to the same period in 2025 was
primarily driven by a $7.8 million decrease in nonrecurring noncash income from
an equity method investment recognized in 2025, a $5.9 million increase in
noncash interest expense related to deferred royalty obligations, and a $4.2
million decrease in other income resulting from changes in the valuation of the
embedded derivative liability component of our deferred royalty obligation.
These changes were partially offset by an $8.5 million decrease in net loss from
equity method investments and a $6.9 million increase in interest income.
8
The increase in total other income (expense), net of $3.1 million for the nine
months ended September 30, 2026, compared to the same period in 2025 was
primarily driven by a $37.0 million increase in noncash interest expense related
to deferred royalty obligations, a $7.8 million decrease in nonrecurring noncash
income from an equity method investment recognized in 2025, a $4.9 million
decrease in net gains on foreign currency transactions, and a $4.0 million
decrease in other income resulting from changes in the valuation of the embedded
derivative liability component of our deferred royalty obligation. These changes
were partially offset by a $21.2 million decrease in loss on extinguishment of
debt recognized in the first quarter of 2025, a $19.5 million decrease in net
loss from equity method investments, and a $10.5 million increase in interest
income.
Net Loss Attributable to Common Stockholders of BridgeBio and Net Loss per Share
For the three and nine months ended September 30, 2026, the Company recorded a
net loss attributable to common stockholders of BridgeBio of $83.0 million and
$399.3 million, respectively, compared to $182.7 million and $532.1 million,
respectively, for the same periods in 2025.
For the three and nine months ended September 30, 2026, the Company reported a
net loss per share of $0.42 and $2.04, respectively, compared to $0.95 and
$2.79, respectively, for the same periods in 2025.
BRIDGEBIO PHARMA, INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
Thr… Nine
Mon… Mon…
End… End…
Sep… Sep…
30, 30,
2026 2026
R… (Un… 20… (Un… 20…
──────────────────────────────────────────────────────────────────────────────
N…
p… $ 25… $ 108… $ 65… $ 216…
r…
L…
a… 79… 8,3… 89… 125…
s…
r…
R… 20… 4,2… 45… 6,1…
r…
T…
r… 35… 120… 79… 347…
n…
O…
c…
a…
e…
C…
of
r…
C…
of 12… 4,0… 30… 8,9…
g…
s…
C…
of
l…
s… 8,… 2,5… 14… 3,9…
a…
r…
r…
T…
c… 20… 6,5… 45… 12,…
of
r…
R…
a… 14… 112… 41… 335…
d…
S…
g… 20… 137… 55… 373…
a…
a…
R…
i…
a… — 8,8… — 10,…
r…
c…
T…
o…
c… 36… 265… 1,… 731…
a…
e…
L…
f… -1… -14… -2… -38…
o…
O…
i…
(…
n…
I… 13… 6,2… 26… 15,…
i…
I… -1… -11… -3… -41…
e…
N…
i…
e…
on -4… -36… -1… -86…
d…
r…
o…
N…
l…
f… -7… -15… -3… -51…
e…
m…
i…
L…
on
e… — — — -21…
of
d…
O…
i… 2,… 16,… 11… 31,…
n…
T…
o… -4… -41… -1… -15…
e…
n…
L…
b… -5… -18… -3… -53…
i…
t…
P…
f…
(… 1,… -1,… 1,… 555
f…
i…
t…
N… -6… -18… -3… -53…
l…
N…
l…
a…
to
r…
c… 3,… 2,1… 9,… 6,2…
n…
i…
a…
n…
i…
N…
l…
a… -5… -18… -3… -53…
to
B…
P…
s…
d… 26… — 26… —
a…
a…
N…
l…
a…
to $ -8… $ -18… $ -3… $ -53…
c…
s…
of
B…
N…
l…
p…
s…
a…
to
c… $ -0… $ -0.… $ -2… $ -2.…
s…
of
B…
b…
a…
d…
W…
s…
u…
in
c…
n…
l…
p…
s… 196… 19… 195… 19…
a…
to
c…
s…
of
B…
b…
a…
d…
10
Three Nine
Months Months
Ended Ended
Septem… Septe…
30, 30,
Stock… 2026 2026
Compe… (Unaud… 2025 (Unau… 2025
──────────────────────────────────────────────────────────────────────────────
Cost
of $ 374 $ 361 $ 2,029 $ 578
goods
sold
Resea…
and 14,921 12,328 42,504 37,582
devel…
Selli…
gener… 24,562 21,866 73,209 63,077
and
admin…
Restr…
impai…
and — 709 — 755
relat…
charg…
Total
stock… $ 39,857 $ 35,264 $ 117,742 $ 101,9…
compe…
11
BRIDGEBIO PHARMA, INC.
Condensed Consolidated Balance Sheets
(In thousands)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
-Unaudited -1
Assets
Cash, cash equivalents and
marketable $ 1,538,855 $ 587,482
securities
Accounts receivable, net 375,089 139,444
Inventories 59,718 26,753
Prepaid expenses and other
current 70,944 44,070
assets
Total current assets 2,044,606 797,749
Equity method investments 47,783 79,972
Property and equipment, net 5,042 5,366
Operating lease 15,746 8,149
right-of-use assets
Intangible assets, net 25,923 28,077
Other assets 22,686 16,712
Total assets $ 2,161,786 $ 936,025
Liabilities, Redeemable
Convertible
Noncontrolling Interests
and
Stockholders' Deficit
Accounts payable $ 88,258 $ 36,228
Operating lease
liabilities, current 1,987 6,192
portion
Deferred revenue, current 4,744 7,190
portion
2027 Notes, net 548,430 —
Accrued and other current 333,818 238,361
liabilities
Total current liabilities 977,237 287,971
Operating lease
liabilities, net of 14,645 3,811
current portion
Deferred revenue, net of 8,968 13,080
current portion
2027 Notes, net — 547,015
2029 Notes, net 742,437 740,890
2031 Notes, net 566,013 564,565
2033 Notes, net 620,533 —
Deferred royalty 884,053 855,030
obligations, net
Other long-term liabilities 1,405 244
Redeemable convertible
noncontrolling -1,363 -570
interests
Series A preferred stock 942,478 —
Common stock 207 202
Treasury stock, at cost -580,775 -323,276
Additional paid-in capital 2,170,006 2,057,646
Accumulated other
comprehensive income -95 12
(loss)
Accumulated deficit -4,194,163 -3,821,194
Noncontrolling interests 10,200 10,599
Total liabilities,
redeemable
convertible noncontrolling $ 2,161,786 $ 936,025
interests and
stockholders' deficit
12
BRIDGEBIO PHARMA, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands)
Nine Months Ended
September 30,
2026
Operating activities: (Unaudited) 2025
──────────────────────────────────────────────────────────────────────────────
Net loss $ -382,942 $ -538,303
Adjustments to
reconcile net loss to
net
cash used in operating
activities:
Noncash interest
expense on deferred 123,500 86,460
royalty obligations
Stock-based 117,171 98,385
compensation
Net loss from equity 32,030 51,579
method investments
Change in fair value
of the embedded
derivative associated -7,098 -11,062
with the deferred
royalty obligation
Amortization of debt
discount and 5,670 4,515
issuance costs
Depreciation and 3,308 3,999
amortization
Noncash lease expense 4,714 3,443
Loss on extinguishment — 21,155
of debt
Noncash income from an
equity method — -7,769
investment
Other noncash 2,233 -1,217
adjustments, net
Changes in operating
assets and
liabilities:
Accounts receivable, -235,646 -111,796
net
Inventories -35,641 -23,356
Prepaid expenses and
other current -26,872 -17,527
assets
Other assets -5,849 568
Accounts payable 51,993 9,084
Accrued compensation -9,049 3,212
and benefits
Accrued research and
development 13,583 347
liabilities
Operating lease -5,494 -4,757
liabilities
Deferred revenue -6,558 -9,480
Other liabilities 48,397 53,030
Net cash used in -312,550 -389,490
operating activities
Investing activities:
Purchases of -63,937 -10,876
marketable securities
Maturities of 76,500 8,000
marketable securities
Proceeds from special
cash dividends
received from an — 2,302
investment in equity
securities
Payment for intangible — -8,495
assets
Purchases of property -802 -1,064
and equipment
Net cash provided by
(used in) investing 11,761 -10,133
activities
Financing activities:
Proceeds from issuance 632,500 —
of 2033 Notes
Issuance costs and
discounts associated -13,227 —
with 2033 Notes
Proceeds from issuance — 575,000
of 2031 Notes
Issuance costs and
discounts associated — -12,034
with 2031 Notes
Repayment of term — -459,000
loans
Proceeds from royalty
obligation under
Royalty Purchase — 300,000
Agreement (as
described
in Note 9)
Issuance costs
associated with
royalty — -3,010
obligation under
Royalty Purchase
Agreement
Repayments of deferred
royalty -62,507 -6,896
obligations
Proceeds from issuance
of preferred 933,900 —
stock
Issuance costs
associated with -1,342 —
preferred
stock
Payment of preferred -2,694 —
stock dividends
Repurchase of common -252,502 -48,276
stock
Proceeds from stock
option exercises, 33,712 14,523
net of repurchases
Proceeds from common
stock issuances 9,728 6,414
under ESPP
13
Repurchase of RSU shares to satisfy tax -13,431 -6,796
withholding
Transactions with noncontrolling — 1,550
interests
Net cash provided by financing 1,264,137 361,475
activities
Net increase (decrease) in cash, cash 963,348 -38,148
equivalents, and restricted cash
Cash, cash equivalents, and restricted 572,140 683,244
cash at beginning of period
Cash, cash equivalents, and restricted $ 1,535,488 $ 645,096
cash at end of period
Supplemental Nine Months Ended
Disclosure of Cash September 30,
Flow 2026
Information: (Unaudited) 2025
──────────────────────────────────────────────────────────────────────────────
Cash paid for interest $ 43,135 $ 43,670
Supplemental
Disclosures of Noncash
Investing and
Financing Information:
Accretion of preferred $ 9,920 $ —
stock
Accrued cash dividends
on preferred $ 13,679 $ —
stock
Accrual for repurchase $ 4,997 $ —
of common stock
Transfers to
noncontrolling $ -8,765 $ -4,734
interests
Reconciliation of
Cash, Cash Equivalents
and Restricted Cash:
Cash and cash $ 1,533,363 $ 642,951
equivalents
Restricted cash —
Included in “Prepaid 550 126
expenses and other
current assets”
Restricted cash —
Included in “Other 1,575 2,019
assets”
Total cash, cash
equivalents and
restricted cash at end
of periods shown on $ 1,535,488 $ 645,096
the condensed
consolidated
statements of cash
flows
Webcast Information
BridgeBio will host a conference call and webcast to discuss third quarter
financial results today, October 29, 2026, at 4:30 pm ET. This event can be
accessed at https://events.q4inc.com/attendee/463906479 or by visiting the
“Events & Presentations” page within the Investors section of the BridgeBio
website at investor.bridgebio.com . A replay of the webcast will be available on
the BridgeBio website for 30 days following the event.
About Attruby
® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the
cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-
CM) in adults to reduce cardiovascular death and cardiovascular-related
hospitalization.
IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported
in patients treated with Attruby versus placebo, respectively. The majority of
these adverse reactions were mild and resolved without drug discontinuation.
Discontinuation rates due to adverse events were similar between patients
treated with Attruby versus placebo (9.3% and 8.5%, respectively).
14
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions.
Millions of people worldwide living with genetic conditions lack treatment
options, often because drug development for small patient populations can be
commercially challenging. We aim to bridge the gap between advancements in
genetic science and meaningful medicines for underserved patient populations.
Our decentralized, hub-and-spoke model is designed for speed, precision, and
scalability. Autonomous and empowered teams focus on individual conditions,
while a central hub provides the clinical, regulatory, and commercial
capabilities needed to bring innovation to market. For more information, visit
bridgebio.com
and follow us on
LinkedIn
,
X
,
Facebook
,
Instagram
,
YouTube
, and
TikTok
.
BridgeBio Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press
release may include statements that are not historical facts and are considered
forward-looking within the meaning of Section 27A of the Securities Act of 1933,
as amended (the Securities Act), and Section 21E of the Securities Exchange Act
of 1934, as amended (the Exchange Act), which are usually identified by the use
of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,”
“hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,”
“will,” and variations of such words or similar expressions. BridgeBio intends
these forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 27A of the Securities Act and
Section 21E of the Exchange Act. These forward-looking statements, including
express and implied statements relating to the continued commercial success and
market potential of Attruby/Beyonttra (acoramidis); the Company’s expectations
regarding timing of regulatory submissions and target action dates, approvals
and commercial launches in the U.S. and Europe, including for BBP-418 for
LGMD2I/R9, encaleret for ADH1, and oral infigratinib for achondroplasia; the
Company’s expectations regarding the timing and outcome of pre-commercial
activities, including activities designed to support three potential launches;
the timing of the Company’s clinical trials, milestones and expected updates for
its various programs and pipeline; the safety and the potential benefits of the
Company’s product and product candidates; the Company’s anticipated
presentations of data; and the Company’s belief that its cash, cash equivalents
and marketable securities will enable the Company to fund its three potential
launches and expansion indications across its pipeline. Such statements reflect
the Company’s current views about the Company’s plans, intentions, expectations
and strategies, which are based on the information currently available to it and
on assumptions the Company has made. Although the Company believes that its
plans, intentions, expectations and strategies as reflected in or suggested by
those forward-looking statements are reasonable, the Company can give no
assurance that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be affected by a
number of risks, uncertainties and assumptions, including, but not limited to,
initial and ongoing data from the Company’s preclinical studies and clinical
trials not being indicative of final data, the potential size of the target
patient populations the Company’s product candidates are designed to treat not
being as large as anticipated, the design and success of ongoing and planned
clinical trials, future regulatory filings, approvals and/or sales, despite
having ongoing and future interactions with the FDA or other regulatory agencies
to discuss potential paths to registration for the Company’s product candidates,
the FDA or such other regulatory agencies not agreeing with the Company’s
regulatory approval strategies, components of the Company’s filings, such as
clinical trial designs, conduct and methodologies, or the sufficiency of data
submitted, the Company’s pre-commercial activities, commercial launches or
operational execution not occurring on anticipated timelines or not supporting
planned launches as expected, real-world experience with Attruby/Beyonttra not
being consistent with observed biochemical differentiation or not translating
into differentiated clinical, commercial or market outcomes, the continuing
success of the Company’s collaborations, the Company’s ability to obtain
additional funding, including through less dilutive sources of capital than
equity financings, potential volatility in
15
the Company’s share price, the Company’s share repurchase program being
modified, suspended or discontinued, or share repurchases not delivering the
anticipated benefits or proving to be a more attractive use of capital than
other alternatives, the impacts of current macroeconomic and geopolitical
events, including changing conditions from hostilities in Ukraine and the Middle
East, increasing rates of inflation and changing interest rates, on business
operations and expectations, as well as those risks set forth in the Risk
Factors section of the Company’s most recent Quarterly Report on Form 10-Q and
Annual Report on Form 10-K and the Company’s other filings with the U.S.
Securities and Exchange Commission. Moreover, the Company operates in a very
competitive and rapidly changing environment in which new risks emerge from time
to time. These forward-looking statements are based upon the current
expectations and beliefs of the Company’s management as of the date of this
press release, and are subject to certain risks and uncertainties that could
cause actual results to differ materially from those described in the forward-
looking statements. Except as required by applicable law, BridgeBio assumes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
[email protected]
(650)-789-8220
BridgeBio Investor Contact:
BridgeBio Investor Relations
[email protected]
16